Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Esposito

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumabChiara Pirrone, Umberto Malapelle, Francesco Pepe, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumabChiara Pirrone, Umberto Malapelle, Francesco Pepe, et al.
Pageof 10